J Gen Virol Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Published online ahead of print on 4 March 2009 as doi:10.1099/vir.0.009308-0
Journal of General Virology 2009;90:1119.

A more recent version of this article appeared on May 1, 2009 J Gen Virol (2009), DOI 10.1099/vir.0.009308-0
© 2009 Society for General Microbiology
This Article
Right arrow Full Text (Papers in Press[PDF])
Right arrow All Versions of this Article:
vir.0.009308-0v1
90/5/1119    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miao, C.
Right arrow Articles by Haynes, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miao, C.
Right arrow Articles by Haynes, L. M.
Agricola
Right arrow Articles by Miao, C.
Right arrow Articles by Haynes, L. M.

Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediate reduced pulmonary inflammation in mice

Congrong Miao1, Gertrud U. Radu1, Hayat Caidi1, Ralph A. Tripp2, Larry J. Anderson1 and Lia M. Haynes1,3

1 Centers for Disease Control and Prevention;
2 University of Georgia

3 E-mail: loh5{at}cdc.gov

Therapeutic treatment with a non-neutralizing monoclonal antibody (131-2G) specific to respiratory syncytial virus (RSV) G glycoprotein mediates virus clearance and decreased leukocyte trafficking and interferon gamma (IFN-{gamma}) production in the lungs of RSV-infected mice. Its F(ab')2 component only mediates decreased leukocyte trafficking and IFN-{gamma} production without reducing virus replication. Thus, this monoclonal antibody has two independent actions that could facilitate treatment and/or prevention of RSV infection by both reducing virus replication and virus induced pulmonary inflammation.

Received 1 December 2008; accepted 26 January 2009.


This article has been cited by other articles:


Home page
 J. Immunol.Home page
E. J. Collarini, F. E.-H. Lee, O. Foord, M. Park, G. Sperinde, H. Wu, W. D. Harriman, S. F. Carroll, S. L. Ellsworth, L. J. Anderson, et al.
Potent High-Affinity Antibodies for Treatment and Prophylaxis of Respiratory Syncytial Virus Derived from B Cells of Infected Patients
J. Immunol., November 15, 2009; 183(10): 6338 - 6345.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
INT J SYST EVOL MICROBIOL MICROBIOLOGY J GEN VIROL
J MED MICROBIOL ALL SGM JOURNALS
Copyright © 2009 by the Society for General Microbiology.